It is 11 p.m. on a Tuesday in Seoul. Your throat is on fire, every clinic on your street is dark, and work starts at nine. So you open an app, tap through a menu of symptoms, and a doctor calls you within minutes. Ten minutes later, a prescription is waiting at a pharmacy near your apartment. Millions of Koreans have done exactly this since 2020. Strangely, though, none of it has ever rested on a permanent law. That changes on December 24, 2026, when the Korea telemedicine law finally takes effect.
The amendment to the Medical Service Act passed the National Assembly on December 2, 2025. It was promulgated three weeks later and given a one-year grace period. In other words, Korea is about to turn a pandemic stopgap into a permanent part of its health system. However, the details that matter most are still being fought over this month. They include how many days of medicine a new patient can get, and how far away the doctor may be.
For foreign residents, this decides whether the app on your phone keeps working the way it does now. For investors, meanwhile, it decides whether Korean telehealth apps become a real industry or stay a regulatory gamble. Here is what the law says, what remains open, and who stands to win.
Why the Korea Telemedicine Law Took 15 Years
Most outsiders assume a country this wired would have legalized video doctor visits long ago. After all, Korea has some of the fastest internet on earth. Yet the first bill to allow remote care was submitted in 2010, during the 18th National Assembly. It died. So did several more over the following decade.
The reason was organized resistance. The Korean Medical Association, the main lobby for doctors, argued that screen-based care was unsafe and would hollow out neighborhood clinics. Civic groups added a second objection. They feared that remote care would open the door to profit-driven, commercialized medicine. Consequently, every attempt stalled in committee.
There is also a structural reason. Korea’s health system runs on small, privately owned clinics that are paid per visit. Indeed, a patient in Seoul can usually walk into a specialist the same day. That ease of access is a point of national pride, as we explained in our look at what the world can learn from Korea’s healthcare system. As a result, many doctors saw telemedicine as a solution to a problem Korea did not have. Worse, they saw it as a channel that would let big hospitals and platforms steal their patients.
Then came COVID-19.
From Pandemic Stopgap to a National Habit
In February 2020, the government used its infectious disease law to allow remote consultations temporarily. It was meant to keep coughing patients out of waiting rooms. Instead, it created a habit. Under national health insurance alone, remote consultations rose from about 1.37 million in 2020 to roughly 3.57 million in 2022. By July 2024, the cumulative total under health insurance had passed 10 million.
Notably, these were not exotic cases. The single most common diagnosis was essential hypertension. Type 2 diabetes, acute bronchitis and cholesterol disorders followed close behind. In short, Koreans used the apps for routine, repeat care.
When the pandemic emergency ended, the legal basis disappeared too. So in June 2023, the government replaced it with a tightly restricted pilot program. First-time patients were largely shut out unless they lived on remote islands or in mountain villages. Predictably, usage collapsed. Several of the roughly 30 platforms then operating closed or suspended service that summer. In December 2023, the government loosened the pilot again. It allowed first-time patients to use the service at night and on holidays, as the Korea Times reported at the time.
Still, the next twist came from an unlikely source: a doctors’ strike. In February 2024, thousands of trainee doctors walked out over a plan to expand medical school admissions. In response, the government fully lifted the remaining telemedicine restrictions on February 23, 2024. Ironically, the doctors who had blocked remote care for a decade had just handed it its biggest boost.
By 2026, the industry body for telehealth platforms estimated that about 15 million remote consultations had taken place over six years. Moreover, it said the vast majority had gone through private apps. That figure is the backdrop to the Korea telemedicine law. Korea was no longer debating whether to allow telemedicine. Instead, it was deciding how to regulate something millions of people already used.
What the Korea Telemedicine Law Actually Allows
The final law is a compromise, and it shows. The Ministry of Health and Welfare summarizes it in four principles.
- In-person care comes first. Telemedicine is defined as a supplement, not a replacement.
- Neighborhood clinics lead. Remote care centers on primary-care clinics, not large hospitals.
- Returning patients are the priority. The system is built around people a doctor has already seen.
- No telemedicine-only clinics. A clinic cannot exist purely to serve patients through a screen.
Within that frame, first-time patients are allowed, but with strings attached. A new patient may only request a remote visit from a clinic within their area of residence. In addition, doctors face tighter limits on what they can prescribe to new patients, and for how many days.
Several safeguards apply to everyone. For instance, narcotics and psychotropic drugs cannot be prescribed remotely. Remote prescriptions must also travel as electronic prescriptions through an official system. Furthermore, doctors and pharmacists must check the national drug-safety database, known as DUR, whenever they handle controlled psychotropic drugs. That rule applies to in-person visits too, with fines of up to 1 million won for violations.
Can Medicine Be Delivered to Your Door?
This is the question foreign readers ask most, and the honest answer is: mostly not yet. Under the Korea telemedicine law, pharmacies may hand medicine to someone outside the pharmacy only for five groups. These are residents of islands and remote areas, long-term care recipients, registered disabled people, patients with Class 1 or 2 infectious diseases, and rare-disease patients. Everyone else will still collect prescriptions in person, or send someone to do it.
New Rules for the Apps Themselves
For the first time, the law also defines telemedicine platforms. Any company that wants to run one must register with the health ministry. Platforms above a certain user threshold must also apply for official certification, which the ministry can revoke.
The list of banned behavior is long. Platforms may not interfere in a doctor’s medical judgment or encourage the misuse of medicine. They may not take payments for steering patients or prescriptions to particular clinics or pharmacies. Likewise, they may not nudge patients toward a specific hospital, pharmacy or drug. In practice, that bans much of the affiliate-style marketing common in consumer apps elsewhere.
The Fine Print Still Being Written
The Korea telemedicine law leaves its hardest details to the health ministry. Yet a law that says “the ministry will set the details” is only half a law. Right now, Korea is writing the other half of its Korean telemedicine rules. The health ministry was expected to publish its draft enforcement rules in October, barely two months before launch. Meanwhile, three issues dominate the negotiations.
First, how many days of medicine can a new patient get? During the pilot, a first-time patient could receive up to 90 days of medication in one go. Doctors and pharmacists want that cut sharply. For example, the Korean Pharmaceutical Association has proposed three days for acute illness and seven days for chronic conditions. By contrast, Health Minister Jeong Eun-kyeong told lawmakers on October 8 that the ministry is considering a seven-day default. However, that could stretch to 30 days when a patient’s prior treatment history can be confirmed. Clinic owners immediately pushed back against the 30-day exception.
Second, how local is “local”? The Korea telemedicine law limits new patients to clinics in their area of residence, but it does not define the area. Pharmacists want it drawn at the city, county or district level. Reports in September suggested the ministry was leaning toward the wider province level instead. Platforms, for their part, argue that more than 60% of users reach out-of-area clinics at night or on holidays, when their usual doctor is closed.
Third, which drugs should be off limits? Narcotics are already banned under the Korea telemedicine law. The fight now is over popular non-reimbursed drugs, especially obesity injections and hair-loss pills. Pharmacists want hair-loss and acne treatments added to the banned list. Some also want antibiotics and steroids blocked for first visits. If you have followed the boom in weight-loss drugs, covered in our report on Korea’s GLP-1 tourism trend, you can see why this one is so contentious.
There are quieter proposals too. According to trade press reports, regulators are weighing a cap of about 25 remote prescriptions per pharmacy per day. They are also considering a limit on the share of a clinic’s total visits that can be remote. Both are designed to stop “telemedicine mills.” Neither is final.
As Dailypharm’s English edition notes, the three camps hold sharply different positions. Doctors and pharmacists want remote care kept small and supplementary. Platforms want it convenient enough that people actually use it. The ministry, as usual, is trying to split the difference.
Doctor Now and the Platform War Over Korean Telehealth Apps
No company has more riding on the Korea telemedicine law than Doctor Now. The Seoul startup launched in November 2020 and grew into the country’s largest telemedicine platform. In 2024, it handled more than 760,000 consultations. By December of that year, it was running about 117,000 visits a month, roughly ten times the level a year earlier. In the first half of 2026 alone, it recorded more than 1.45 million consultations. The company also reports 8.55 million cumulative downloads and 4.5 million registered users.
Doctor Now’s reach goes beyond patients. In 2024, about 17,100 pharmacies filled prescriptions that came through the app. That is roughly 68% of every pharmacy in Korea. In other words, most of the pharmacy sector already depends on a platform it publicly opposes.
That tension produced the most heated side battle of the year. Because drug delivery was banned, Doctor Now set up a drug wholesale subsidiary. It then used the arrangement to show patients which nearby pharmacies had their medicine in stock. Pharmacists called it a new form of kickback that tied pharmacies to the platform. As a result, lawmakers drafted an amendment to the Pharmaceutical Affairs Act that bars telemedicine platforms from holding wholesale licenses. Critics quickly nicknamed it the “Doctor Now prevention act.”
The startup community fought back hard. Industry groups compared it to the 2020 law that killed Tada, a popular ride-hailing service, after taxi drivers protested. Even so, the bill passed the National Assembly on August 20, 2026. On the same day, the health ministry said it would review allowing full drug delivery for telemedicine patients. Many observers read that as a peace offering to the platforms. Doctor Now said it regretted the ban but welcomed the move toward legal delivery. Our broader look at how Korean startup regulation shapes new industries explains why this pattern keeps repeating.
What Certification Means for Remote Care in Korea
Here is the part investors should watch closely. Under the Korea telemedicine law, the largest Korean telehealth apps will need government certification. On paper, that is a burden. In practice, it may become a moat. A certified platform with millions of users, thousands of partner clinics and integration with the public e-prescription system will be very hard to dislodge. Smaller rivals, by contrast, may struggle to meet the compliance bill.
At the same time, the law allows the state to build public infrastructure, including the electronic prescription network. Some lawmakers have floated a government-run platform as well. Whether patients would choose a state app over a polished private one is an open question. Nevertheless, it is a risk that did not exist two years ago.
A Second Korea Telemedicine Law for Foreign Patients
While lawmakers argued over the Korea telemedicine law, the government quietly passed a much more permissive law for overseas patients. On May 26, 2026, the health ministry announced the promulgation of an amended Act on Support for Overseas Medical Expansion and Attraction of Foreign Patients. According to the Korea Times, it will take effect next year after a 12-month grace period.
The contrast with the domestic regime is striking. Under the foreign-patient law, doctors, dentists and traditional medicine practitioners at designated institutions may consult and diagnose overseas patients remotely. They may also monitor them and issue prescriptions. Crucially, first-time remote appointments are allowed, and large general hospitals can take part. The government also plans to build a dedicated international telemedicine platform.
The logic is commercial. Korea drew a record 2.01 million international patients last year. Most stay only briefly, which makes pre-surgery counseling and follow-up care difficult. Remote care solves that. A patient in Dubai or Jakarta can consult a Seoul surgeon before booking a flight, then check in after flying home. We mapped the wider industry in our feature on Korea’s medical tourism boom.
There is an important caveat, however. This second law targets patients abroad. If you live in Korea, you will most likely fall under the stricter domestic Korea telemedicine law, like everyone else here.
Remote Care in Korea for Foreign Residents: A Practical Guide
So what does all this mean if you live in Seoul, Busan or Daejeon? Here is a short, practical guide based on how the system works today and what the Korea telemedicine law changes.
You can probably use it already. Remote consultations are tied to the clinic, not to your passport. If you are enrolled in national health insurance, the visit is billed like an ordinary one. That said, most Korean telehealth apps are built for Korean speakers. Sign-up usually requires identity verification through a mobile phone registered in your own name. Consequently, newcomers without a Korean phone contract often hit a wall at step one.
Expect Korean-language screens. The big domestic apps rarely offer full English interfaces. Translation tools help, and many younger doctors speak some English. Still, it is worth asking a Korean-speaking friend to help with your first sign-up.
Plan to pick up your medicine. Under the Korea telemedicine law, unless you fall into one of the five exempt groups, you will still collect prescriptions at a pharmacy. Usefully, you can usually choose one close to home. If Korean pharmacies are new to you, our short guide to how the Korea pharmacy system works is a good primer.
Build a relationship with one clinic. After December 24, returning patients get the most flexibility. Therefore, if you have a chronic condition, see a nearby clinic in person once. Future remote visits will then count as follow-ups rather than first visits.
Don’t expect lifestyle drugs on demand. If regulators add obesity and hair-loss treatments to the restricted list, first-time remote prescriptions for them may disappear. Book an in-person visit instead.
Use it for what it does best. Colds, flu symptoms, skin flare-ups, repeat prescriptions and late-night questions are the sweet spot. Chest pain, breathing problems or serious injuries still mean the emergency room. In Korea, that number is 119.
Investor Take: Who Wins After December 24
For investors watching remote care in Korea, the picture is more nuanced than “legal equals good.”
The winners are likely to be scale players. Certification, e-prescription integration and compliance costs all favor the largest platforms. Doctor Now has the user base, while rivals such as Goodoc bring hospital booking networks. Either could become the default front door to primary care. Notably, Doctor Now has already tested its model abroad, with a Japanese subsidiary launched in 2024.
Pharmacies are reluctant winners. They opposed the platforms but now depend on them for traffic. If delivery is gradually widened, pharmacies with fast dispensing and good stock data will capture most of that volume.
AI is the next layer. Korean startups are already building triage chatbots, symptom checkers and medical-record tools. Our report on how Korean medical AI is entering its revenue era shows how fast that market is moving. A legal telemedicine channel gives those tools a direct path to patients.
The risks are regulatory, not technical. The Korean telemedicine rules could still be written tightly enough to shrink the market. A seven-day cap on first-visit prescriptions, a province-level boundary and a long banned-drug list would each chip away at convenience. Furthermore, Korea has a record of reversing course when a powerful professional group objects. The Tada episode is never far from founders’ minds.
In short, the Korea telemedicine law removes existential risk but adds regulatory friction. For a platform with millions of users, that is a trade worth taking. For a startup still looking for traction, it may be the end of the road.
A Country Catching Up With Its Own Habits
Korea did not legalize telemedicine because it suddenly embraced the idea. Rather, it legalized it because its citizens had already moved on. Millions of people now see a doctor through their phones at night, on holidays and between meetings. The National Assembly has simply caught up.
What remains to be seen is how generous the rules under the Korea telemedicine law will be. If the ministry leans toward doctors and pharmacists, remote care in Korea will stay a narrow tool for returning patients. If it leans toward patients and platforms, it could become as ordinary as ordering lunch through an app.
Either way, December 24 is a turning point for the Korea telemedicine law and for the people who rely on it. For the first time since 2010, the question is no longer whether Koreans may see a doctor through a screen. Instead, it is how far the state will let that idea go. For foreign residents and investors alike, the next ten weeks of rule-writing are worth watching closely.
